ALLO Healthcare

Allogene Therapeutics, Inc.

$1.12+2.75%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 386.9M USD
Enterprise value: 133.4M USD
Full-time employees: 150

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 59% from December 2022 to December 2025.
Allogene Therapeutics had 59% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Allogene Therapeutics had 59% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Annual revenue fell three years running. Fiscal-year revenue down each year from 2022 to 2025.
Allogene Therapeutics's fiscal-year revenue declined in each of the three years to 2025.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Allogene Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Allogene Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

49/ 100

Oct 5 49 → Nov 4 49

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-42.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-126.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-26.5%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield112.7%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

93/100

Strong

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth253.5%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

4/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-3886.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-30.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -5.92Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-35.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.04Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-37.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.48

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.44Sector median: 0.6250 · MAD: 0.3380

Current ratio10.72×

SEC filings · latest balance sheetReported value33% base weight · Z-score 5.87Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.18×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.20Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Allogene Therapeutics

Is Allogene Therapeutics getting weaker?: Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.
How is Allogene Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -42.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -42.8% vs peers 1.5% (weaker than 100% of peers).
Is Allogene Therapeutics growing?: Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 253.5% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 253.5% vs peers 5.8% (stronger than 95% of peers).
How profitable is Allogene Therapeutics?: Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -3886.1% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3886.1% vs peers 7.1% (weaker than 100% of peers).
How risky is Allogene Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.72× vs a peer median of 2.59× (stronger than 88% of peers).Current ratio 10.72× vs peers 2.59× (stronger than 88% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 12, 2026 · compared with the quarter ended Dec 31, 2025

No major changes

Worth watching: Allogene Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	0 USD	4.6M USD	turned positive
Net income (12 months)	−173.8M USD	−165.5M USD	−4.8%
Free cash flow (12 months)	−109.5M USD	−102.6M USD	−6.3%
Cash	30.3M USD	38.6M USD	+27.4%
Shares outstanding	345.2M	345.5M	+0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-157.9%	-215087.2%	-344986.3%	-1241813.6%	—	—
Net margin	-159.6%	-218214.1%	-344489.5%	-1170863.6%	—	—
Return on assets (ROA)	-17.3%	-41.4%	-50.9%	-46.9%	-45.9%	▲ 1.0 pts
Return on equity (ROE)	-19.7%	-51.0%	-63.9%	-61.0%	-65.3%	▼ 4.2 pts
Free cash flow margin	-180.8%	-144685.9%	-251841.1%	-913609.1%	—	—
Current ratio	9.84×	9.84×	12.38×	8.54×	7.93×	▼ 7.2%
Interest coverage	—	—	—	-1509.39×	-194.71×	▲ 87%

ALLO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 59% from December 2022 to December 2025.

Allogene Therapeutics had 59% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Allogene Therapeutics had 59% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Annual revenue fell three years running. Fiscal-year revenue down each year from 2022 to 2025.

Allogene Therapeutics's fiscal-year revenue declined in each of the three years to 2025.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Allogene Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Allogene Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Allogene Therapeutics

Is Allogene Therapeutics getting weaker?

Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.

How is Allogene Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -42.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -42.8% vs peers 1.5% (weaker than 100% of peers).

Is Allogene Therapeutics growing?

Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 253.5% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 253.5% vs peers 5.8% (stronger than 95% of peers).

How profitable is Allogene Therapeutics?

Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -3886.1% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3886.1% vs peers 7.1% (weaker than 100% of peers).

How risky is Allogene Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.72× vs a peer median of 2.59× (stronger than 88% of peers).Current ratio 10.72× vs peers 2.59× (stronger than 88% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

0 USD

4.6M USD

turned positive

Net income (12 months)

−173.8M USD

−165.5M USD

−4.8%

Free cash flow (12 months)

−109.5M USD

−102.6M USD

−6.3%

Cash

30.3M USD

38.6M USD

+27.4%

Shares outstanding

345.2M

345.5M

+0.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-157.9%

-215087.2%

-344986.3%

-1241813.6%

—

Net margin

-159.6%

-218214.1%

-344489.5%

-1170863.6%

—

Return on assets (ROA)

-17.3%

-41.4%

-50.9%

-46.9%

-45.9%

▲ 1.0 pts

Return on equity (ROE)

-19.7%

-51.0%

-63.9%

-61.0%

-65.3%

▼ 4.2 pts

Free cash flow margin

-180.8%

-144685.9%

-251841.1%

-913609.1%

—

Current ratio

9.84×

12.38×

8.54×

7.93×

▼ 7.2%

Interest coverage

—

-1509.39×

-194.71×

▲ 87%